- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04117815
Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Scalp cooling using cooling caps has been identified as an effective treatment option against CT-induced alopecia in numerous European countries. Originally, crashed ice was used to cause vasoconstriction and consequently diminish CT uptake to hair follicles during CT. Soon, this method turned out impractically and has been displaced by cooling caps which allow a constant cooling of the scalp while easy handling.
However, effectiveness of scalp cooling depends on different factors such as hair texture, chemotherapy regimen, dose of chemotherapy, cooling time, and compliance of the patient.
Recent studies focused on alopecia prevention more than on patients' quality of life and satisfaction. Therefore, data on routine use of cool caps with a focus on efficiency in daily routine and patients' acceptability are missing.
Patient-reported outcomes (PROs) provide results assessed by the use of a patient's report about his or her own health condition "without amendment or interpretation by a clinician or anyone else" and are a valuable source of information when evaluating clinical interventions or treatment toxicity in intervention studies in oncology. PROs can be perfectly used to evaluate the implication of scalp cooling regarding hair preservation but also quality of life outcome which seems even more important.
Women with breast- or gynecological cancer receiving taxane- or anthracycline-based neoadjuvant chemotherapy are included in the study. Chemotherapy can be neoadjuvant, adjuvant or palliative. Up to two lines of chemotherapy are allowed. Scalp cooling with a maintenance temperature of 17°C will be initiated 30 minutes prior to each chemotherapy cycle and stopped 90 minutes after CT. Patients are assessed for alopecia and qualitiy of life.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Tyrol
-
Innsbruck, Tyrol, Austria, 6020
- Medical University Innsbruck, Department of Gynaecology and Obstetrics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study is designed as a clinical trial for women with breast or gyneological cancer, planning to undergo taxane- or anthracyline-based CT in a routine clinical setting.
For the purpose of comparison, a reference sample is included in the study.
Description
Inclusion Criteria:
- Patients with breast or gynecological cancer planning to undergo CT
- CT can be neoadjuvant, adjuvant or palliative
- Up to two lines of CT are allowed. Adjuvant therapy counts as one line
- CT regime is associated with alopecia
- CT must be planned for at least 4 cycles of taxane or anthracyline-based CT regimen
- written informed consent age 18 and older
Exclusion Criteria:
- Migraine
- Cold allergy/Cold Agglutinins/Morbus Raynaud
- Hematological malignancies (Leukemia, non Hodgkins and other generalized lymphomas)
- Manifest scalp metastases
- Overt cognitive impairment
- Insufficient knowledge of German language
Reference Population:
- Patients with breast or gynecological cancer planning to undergo CT
- CT can be adjuvant, neoadjuvant or palliative
- up to two lines of CT are allowed. Adjuvant therapy counts as one line.
- CT regime is associated with alopecia
- CT must be planned for at least 4 cycles of taxane or anthracycline-based CT regime
- Refuse to undergo scalp cooling
- Patients who have been excluded for the study group for the reason of migraine
- written informed consent
- age 18 and older
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
study group
Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line. Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen No alopecia of any reason (up-front) No overt cognitive impairment and fluent in German Written informed consent Age 18 and older |
All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:
Patients (study group and reference group) will be assessed at the following time Points:
The assesments include the following
|
reference group
For the purpose of comparison, a reference sample will be included in the study applying to the following inclusion criteria: Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line. Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen Refuse to undergo scalp cooling Patients who have been excluded for the study group for the reason of migraine Written informed consent Age 18 and older Patients from the reference group complete the same survey as the study group. Group comparisons will be adjusted for baseline body image and reasons for refusal. |
Patients (study group and reference group) will be assessed at the following time Points:
The assesments include the following
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Extent of hair preservation
Time Frame: on average of 15 month
|
Hair preservation assessed by photo documentation using VAS (Visual Analogue Scale (Grade 1: < 25% hair loss; Grade 2: 25-50% of hair loss; Grade 3: 50-75%)
|
on average of 15 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Adverse Events (CTCAE 4.03)
Time Frame: on average of 15 month
|
CTCAE are descriptive terminology for reporting adverse events including a grading for each of these adverse events.
This 5-point grading has a range from mild symptoms requiring no intervention (grade 1) to life-threatening consequences (grade 4) and finally death (grade 5)
|
on average of 15 month
|
Assessment of patient satisfaction (HAIRDEX)
Time Frame: on average of 15 month
|
The Hairdex questionnaire is a reliable and valid instrument for the evaluation of quality of life in patients with hair diseases (i.e.
validated in patients with alopecia diffusa and androgenica).
Using a five-point Likert Scale (never=0 to always =4), the questionnaire encompasses 48 items composing the 5 subscales symptoms, functioning, emotionals, self-confidence and stigmatization.
All scales range from 0-100, higher values indicate higher impairment.
|
on average of 15 month
|
Assessment of quality of life (EORTC) QLQ-C30
Time Frame: on average of 15 month
|
he EORTC QLQ-C30 Aaronson is a self-report measure consisting of 30 items with a 4 point Likert Scale response format.
It targets on functioning (physical, role emotional, cognitive, and social functioning and global health/QoL scale) and symptoms (fatigue, nausea and emesis, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties).
All scales and single items range from 0-100.
|
on average of 15 month
|
Assessment of quality of life (EORTC) BR23
Time Frame: on average of 15 month
|
The 23-item EORTC QLQ BR23 contains two breast cancer specific functional scales (body image and sexuality) and three symptom scales evaluating arm symptoms, breast symptoms, and systemic therapy symptoms.
In addition, we include EORTC single items for hair loss.
|
on average of 15 month
|
Assessment of quality of life (Body Image Scale BIS)
Time Frame: on average of 15 month
|
It is a 10 items short instrument suitable for use in clinical trials.
The BIS has a single sumscore; the response format is a 4-point Likert scale with high values indicating good body image.
|
on average of 15 month
|
Patient reported-outcomes Common Terminology Criteria for Adverse Events (PRO- CTCAE)
Time Frame: on average of 15 month
|
The PRO-CTCAE allow the assessment of those symptoms listed in the CTCAE that can be perceived by a patient him/herself.
For most items PRO-CTCAE assesses symptom severity, but for some it covers also symptom frequency and interference with daily activities.
In total, this PRO instrument covers 81 symptoms with 126 items using a 5-point Likert scale for grading.
For the purpose of this study, we use the PRO-CTCAE-ITEMS (Item Library Version 1.0; Version date: 3/24/2016) Symptom Term: Hair loss.
|
on average of 15 month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Christian Marth, Prof Dr, Medical University Innsbruck
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1049/2018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alopecia
-
Siriraj HospitalCompletedRecalcitrant Alopecia Totalis | Recalcitrant Alopecia UniversalisThailand
-
Aclaris Therapeutics, Inc.CompletedAlopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Yale UniversityCompletedFibrosing Alopecia | Frontal Fibrosing Alopecia | Central Centrifugal Cicatricial AlopeciaUnited States
-
Yale UniversityCompletedAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Wake Forest University Health SciencesThe Skin of Color SocietyRecruitingCentral Centrifugal Cicatricial Alopecia (CCCA)United States
-
M.D. Anderson Cancer CenterNational Alopecia Areata FoundationActive, not recruitingAlopecia Areata | Alopecia Totalis | Alopecia Universalis | Autoimmune Hair Loss | Alopecia PartialisUnited States
-
King Saud UniversitySaudi Society of Dermatology and Dermatologic surgeryCompletedAlopecia Totalis | Alopecia Universalis | Ophiasic AlopeciaSaudi Arabia
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
Erasmus Medical CenterRecruitingAutoimmune Diseases | Alopecia | Alopecia Areata | Hair Diseases | Alopecia Totalis | Alopecia Universalis | Hair Loss | Alopecia DrugsNetherlands
-
EquilliumWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
Clinical Trials on Paxman Scalp Cooling System
-
HonorHealth Research InstituteCompleted
-
The University of Hong KongCompletedGynecologic Cancer | Chemotherapy-Induced ChangeHong Kong
-
Medstar Health Research InstitutePaxmanCompletedBreast Cancer | Ovarian Cancer | Endometrial Cancer | Gynecologic NeoplasmUnited States
-
St. Jude Children's Research HospitalRecruiting
-
City of Hope Medical CenterNational Cancer Institute (NCI)Not yet recruitingAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast CarcinomaUnited States
-
University of California, San FranciscoCooler Heads Care Inc.Not yet recruitingBreast Cancer | Alopecia | Chemotherapy-induced Alopecia | Early-stage Breast Cancer | Hair LossUnited States
-
Montefiore Medical CenterPaxmanRecruiting
-
Cooler Heads Care Inc.Not yet recruitingBreast Cancer | Alopecia | Chemotherapy-induced Alopecia | Hair Loss
-
Cooler Heads Care Inc.WithdrawnBreast Cancer | Gynecologic Cancer | Alopecia | Chemotherapy-induced Alopecia | Hair LossUnited States
-
Tao OUYANGRecruitingPrimary Breast CancerChina